Projekt
A retrospective, Swiss multi-center study to investigate the efficacy of natalizumab in second line therapy
Abgeschlossen · 2008 bis 2009
Putzki Norman
Art
Klinische Forschung
Reichweite
Multizentrisch, KSSG als teilnehmendes Zentrum
Bereiche
Status
Abgeschlossen
Start
2008
Ende
2009
Finanzierungsart
Eigenfinanzierung
Studiendesign
retrospective, non-controlled
Schlagwörter (Tags)
multiple sclerosis, natalizumab, treatment failure
Projektpartner
Biogen Idec
Weitere Informationen
submitted to European Neurology
Kurzbeschreibung/Zielsetzung
Natalizumab is restricted to patients with treatment failure to IFN-beta and to highly active MS. The pivotal trials were not designed to examine this scenario. This study seeks to add at least 100 patient years experience in second line therapy of RRMS.